Summaries are drawn from public sources and link to them. HSH does not give a risk rating: read the summary and sources and reach your own view. Unproven allegations are labelled as such. Suppliers can submit a response, which is shown alongside.
Latest full-year results from official filings.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Credible news about incidents, disputes, legal action or restructuring in the last 24 months.
Sep 2026: Annalise.ai's owner Harrison.ai was reported to have made an undisclosed number of Australian roles redundant after an April 2026 consultation, while reorganising staff around AI agents; its government investor said it was aware of the changes.
Data breaches, cyber incidents, regulator action and assurance status.
No data breaches, cyber incidents or regulator actions involving Annalise.ai or Harrison.ai found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Recalls, safety notices, regulator action and clinical safety concerns.
No product recalls, safety notices or warning letters involving Annalise.ai found in HSH's search of the last 24 months. Mar 2026: Harrison.ai received FDA 510(k) clearance for acute infarct triage on non-contrast CT brain.
Contract delivery, go-lives, terminations and disputes.
No contract terminations, disputes or troubled implementations involving Annalise.ai found in HSH's search of the last 24 months.